Physician profile
David Allan White
NPI 1386730711
$1,096.35
in general payments reported to CMS, 2019-2025
23 companies · $33.19 in 2025
The $33.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $94.02 · 2021: $240 · 2022: $105 · 2023: $148 · 2024: $259 · 2025: $33.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $146.26 | 2019-2024 | Vaxelis, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $137.41 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $131.92 | 2019-2024 | Mounjaro |
| Novo Nordisk INC | $107.93 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $101.61 | 2019-2022 | |
| Abbvie INC. | $74.05 | 2021-2024 | |
| Dexcom, INC. | $57.49 | 2023-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.84 | 2019 | |
| United Therapeutics Corporation | $34.19 | 2021 | |
| Amgen INC. | $33.60 | 2021-2023 | Repatha, Otezla |
| Sanofi Pasteur INC. | $29.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $25.27 | 2021-2022 | |
| Genentech USA, INC. | $22.67 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.07 | 2021 | |
| Axsome Therapeutics, INC. | $16.70 | 2023 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.90 | 2021 | |
| Amarin Pharma, INC. | $15.42 | 2021 | |
| Cequr Corporation | $15.38 | 2025 | Cequr Simplicity |
| Sunovion Pharmaceuticals INC. | $15.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.91 | 2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.48 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.